<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZANTAC- ranitidine hydrochlorideÂ injection, solutionÂ </strong><br>Covis Pharmaceuticals, Inc.<br></p></div>
<h1>ZANTAC<span class="Sup">Â®</span><br>(ranitidine hydrochloride)<br>Injection<br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6de02c0f-3659-4304-93c3-2e207d8bf3ad"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Pharmacy Bulk Packageâ€”Not for Direct Infusion</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_05c1da37-42f8-41c3-bd01-1960c66419e5"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">The active ingredient in ZANTAC Injection is ranitidine hydrochloride (HCl), a histamine H<span class="Sub">2</span>-receptor antagonist. Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-Nâ€²-methyl-2-nitro-1,1-ethenediamine, hydrochloride. It has the following structure:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da7dbbe1-4f2d-4466-9573-8d239d112998&amp;name=f6e057d6-ec9a-45da-ba74-0ebda3fa873c-01.jpg"></div>
<p>The empirical formula is C<span class="Sub">13</span>H<span class="Sub">22</span>N<span class="Sub">4</span>O<span class="Sub">3</span>Sâ—?HCl, representing a molecular weight of 350.87.</p>
<p>Ranitidine HCl is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, granular substance that is soluble in water.</p>
<p>ZANTAC Injection is a clear, colorless to yellow, nonpyrogenic liquid. The yellow color of the liquid tends to intensify without adversely affecting potency. The pH of the injection solution is 6.7 to 7.3.</p>
<p>Each 1Â mL of aqueous solution contains ranitidine 25Â mg (as the hydrochloride); phenol 5Â mg as preservative; and 0.96Â mg of monobasic potassium phosphate and 2.4Â mg of dibasic sodium phosphate as buffers.</p>
<p>A pharmacy bulk package is a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous (IV) infusion. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_e6e4362b-12b3-425d-898e-66924bb12a78"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">ZANTAC is a competitive, reversible inhibitor of the action of histamine at the histamine H<span class="Sub">2</span>-receptors, including receptors on the gastric cells. ZANTAC does not lower serum Ca++ in hypercalcemic states. ZANTAC is not an anticholinergic agent.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0f92c969-1111-4c82-ae77-efbd479dfc97"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First"><span class="Bold"><span class="Italics">Absorption:</span></span> ZANTAC is absorbed very rapidly after intramuscular (IM) injection. Mean peak levels of 576 ng/mL occur within 15 minutes or less following a 50-mg IM dose. Absorption from IM sites is virtually complete, with a bioavailability of 90% to 100% compared with intravenous (IV) administration. Following oral administration, the bioavailability of ZANTAC Tablets is 50%. </p>
<p><span class="Bold"><span class="Italics">Distribution:</span></span> The volume of distribution is about 1.4 L/kg. Serum protein binding averages 15%. </p>
<p><span class="Bold"><span class="Italics">Metabolism:</span></span> In humans, the N-oxide is the principal metabolite in the urine; however, this amounts to &lt;4% of the dose. Other metabolites are the S-oxide (1%) and the desmethyl ranitidine (1%). The remainder of the administered dose is found in the stool. Studies in patients with hepatic dysfunction (compensated cirrhosis) indicate that there are minor, but clinically insignificant, alterations in ranitidine half-life, distribution, clearance, and bioavailability. </p>
<p><span class="Bold"><span class="Italics">Excretion:</span></span> Following IV injection, approximately 70% of the dose is recovered in the urine as unchanged drug. Renal clearance averages 530 mL/min, with a total clearance of 760 mL/min. The elimination half-life is 2.0 to 2.5 hours.</p>
<p>Four patients with clinically significant renal function impairment (creatinine clearance 25 to 35Â mL/min) administered 50Â mg of ranitidine intravenously had an average plasma half-life of 4.8Â hours, a ranitidine clearance of 29Â mL/min, and a volume of distribution of 1.76Â L/kg. In general, these parameters appear to be altered in proportion to creatinine clearance (see <a href="#i4i_dosage_admin_id_6a5691bf-988a-4901-b28e-b556a940ccd7">DOSAGE AND ADMINISTRATION</a>).</p>
<p><span class="Bold"><span class="Italics">Geriatrics:</span></span> The plasma half-life is prolonged and total clearance is reduced in the elderly population due to a decrease in renal function. The elimination half-life is 3.1Â hours (see <a href="#i4i_geriatric_use_id_9c2aa83f-9cdb-420f-83ac-799d012e6b1c">PRECAUTIONS: Geriatric Use</a> and <a href="#i4i_section_id_40a4d9c0-e743-4d4d-bee4-e3e361fa05c1">DOSAGE AND ADMINISTRATION: Dosage Adjustment for Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a>).</p>
<p><span class="Bold"><span class="Italics">Pediatrics:</span></span> There are no significant differences in the pharmacokinetic parameter values for ranitidine in pediatric patients (from 1 month up to 16 years of age) and healthy adults when correction is made for body weight. The pharmacokinetics of ZANTAC in pediatric patients are summarized in <a href="#id_c4af2171-13b1-4925-8c1e-66bc0509afed">Table 1</a>.</p>
<a name="id_c4af2171-13b1-4925-8c1e-66bc0509afed"></a><table width="432.000">
<caption><span>Table 1. Ranitidine Pharmacokinetics in Pediatric Patients Following IV Dosing</span></caption>
<col width="16.7%">
<col width="16.7%">
<col width="16.7%">
<col width="16.7%">
<col width="16.7%">
<col width="16.7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">Population</p>
<p>(age)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">n</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Dose </p>
<p>(mg/kg)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">t<span class="Sub">Â½</span></p>
<p>(hours) </p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Vd</p>
<p>(L/kg)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">CLp </p>
<p>(mL/min/kg) </p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic ulcer disease</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First"> (&lt;6 years)</p></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">1.25 or 2.5</td>
<td class="Botrule Rrule" align="center" valign="top">2.2</td>
<td class="Botrule Rrule" align="center" valign="top">1.29</td>
<td class="Botrule Rrule" align="center" valign="top">11.41</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First"> (6 âˆ’ 11.9 years)</p></td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">1.25 or 2.5</td>
<td class="Botrule Rrule" align="center" valign="top">2.1</td>
<td class="Botrule Rrule" align="center" valign="top">1.14</td>
<td class="Botrule Rrule" align="center" valign="top">8.96</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> (&gt;12 years)</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">1.25 or 2.5</td>
<td class="Botrule Rrule" align="center" valign="top">1.7</td>
<td class="Botrule Rrule" align="center" valign="top">0.98</td>
<td class="Botrule Rrule" align="center" valign="top">9.89</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Adults</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">2.5</td>
<td class="Botrule Rrule" align="center" valign="top">1.9</td>
<td class="Botrule Rrule" align="center" valign="top">1.04</td>
<td class="Botrule Rrule" align="center" valign="top">8.77</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic ulcer disease</span></p>
<p> (3.5 âˆ’ 16 years)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.13 âˆ’ 0.80</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">795Â mL/min/1.73/m<span class="Sup">2</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Children in intensive care</p>
<p> (1 day âˆ’ 12.6 years)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">17</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2.4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">11.7</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Neonates receiving ECMO</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">6.6</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">1.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4.3</p></td>
</tr>
</tbody>
</table>
<p>T<span class="Sub">Â½</span>= Terminal half-life; CLp = Plasma clearance of ranitidine.</p>
<p>ECMO = extracorporeal membrane oxygenation.</p>
<p>Plasma clearance in neonatal patients (less than 1 month of age) receiving ECMO was considerably lower (3 to 4Â mL/min/kg) than observed in children or adults. The elimination half-life in neonates averaged 6.6 hours as compared to approximately 2 hours in adults and pediatric patients. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9f5ea954-9103-4705-8e34-c089728ed13d"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">Serum concentrations necessary to inhibit 50% of stimulated gastric acid secretion are estimated to be 36 to 94Â ng/mL. Following single IV or IM 50-mg doses, serum concentrations of ranitidine are in this range for 6 to 8Â hours. </p>
<p><span class="Bold"><span class="Italics">Antisecretory Activity: 1. Effects on Acid Secretion:</span></span> ZANTAC Injection inhibits basal gastric acid secretion as well as gastric acid secretion stimulated by betazole and pentagastrin, as shown in <a href="#id_b2114bd0-7029-4807-89d6-d9e03811e208">Table 2</a>.</p>
<a name="id_b2114bd0-7029-4807-89d6-d9e03811e208"></a><table width="0.000">
<caption><span>Table 2. Effect of Intravenous ZANTAC on Gastric Acid Secretion</span></caption>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><p class="First">Time After Dose, hours</p></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">
<p class="First">% Inhibition of Gastric Acid Output</p>
<p>by Intravenous Dose, mg</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">20 mg</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">60 mg</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">100 mg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Betazole</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Up to 2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">93</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">99</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">99</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Pentagastrin</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">Up to 3</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">47</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">66</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">77</p></td>
</tr>
</tbody>
</table>
<p>In a group of 10 known hypersecretors, ranitidine plasma levels of 71, 180, and 376Â ng/mL inhibited basal acid secretion by 76%, 90%, and 99.5%, respectively.</p>
<p>It appears that basal- and betazole-stimulated secretions are most sensitive to inhibition by ZANTAC, while pentagastrin-stimulated secretion is more difficult to suppress.</p>
<p><span class="Bold"><span class="Italics">2. Effects on Other Gastrointestinal Secretions:</span></span></p>
<p><span class="Bold"><span class="Italics">Pepsin:</span></span> ZANTAC does not affect pepsin secretion. Total pepsin output is reduced in proportion to the decrease in volume of gastric juice.</p>
<p><span class="Bold"><span class="Italics">Intrinsic Factor:</span></span> ZANTAC has no significant effect on pentagastrin-stimulated intrinsic factor secretion.</p>
<p><span class="Bold"><span class="Italics">Serum Gastrin:</span></span> ZANTAC has little or no effect on fasting or postprandial serum gastrin.</p>
<p><span class="Bold"><span class="Italics">Other Pharmacologic Actions</span></span></p>
<ol>
<li>Gastric bacterial floraâˆ’increase in nitrate-reducing organisms, significance not known.</li>
<li>Prolactin levelsâˆ’no effect in recommended oral or IV dosage, but small, transient, dose-related increases in serum prolactin have been reported after IV bolus injections of 100 mg or more.</li>
<li>Other pituitary hormonesâˆ’no effect on serum gonadotropins, TSH, or GH. Possible impairment of vasopressin release.</li>
<li>No change in cortisol, aldosterone, androgen, or estrogen levels.</li>
<li>No antiandrogenic action.</li>
<li>No effect on count, motility, or morphology of sperm.</li>
</ol>
<p><span class="Bold"><span class="Italics">Pediatrics:</span></span> The ranitidine concentration necessary to suppress basal acid secretion by at least 90% has been reported to be 40 to 60Â ng/mL in pediatric patients with duodenal or <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span>.</p>
<p>In a study of 20 critically ill pediatric patients receiving ranitidine IV at 1Â mg/kg every 6Â hours, 10 patients with a baseline pHâ‰¥4 maintained this baseline throughout the study. Eight of the remaining 10 patients with a baseline of pHâ‰¤2 achieved pHâ‰¥4 throughout varying periods after dosing. It should be noted, however, that because these pharmacodynamic parameters were assessed in critically ill pediatric patients, the data should be interpreted with caution when dosing recommendations are made for a less seriously ill pediatric population.</p>
<p>In another small study of neonatal patients (nÂ =Â 5) receiving ECMO, gastric pH&lt;4 pretreatment increased to &gt;4 after a 2-mg/kg dose and remained above 4 for at least 15Â hours.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_1942c981-62ae-4556-9af5-ee29c47d6d77"></a><a name="section-3.3"></a><p></p>
<h2>Clinical Trials</h2>
<p class="First"><span class="Bold"><span class="Italics">Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span>:</span></span> In a multicenter, double-blind, controlled, US study of endoscopically diagnosed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>, earlier healing was seen in the patients treated with oral ZANTAC as shown in <a href="#id_1090b93c-feea-4279-86f1-edc0a22ee549">Table 3</a>.</p>
<a name="id_1090b93c-feea-4279-86f1-edc0a22ee549"></a><table width="429.000">
<caption><span>Table 3. <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Patient Healing Rates</span></caption>
<col width="20.0%">
<col width="14.5%">
<col width="25.4%">
<col width="14.2%">
<col width="25.9%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><p class="First">Oral ZANTAC<span class="Sup">*</span></p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><p class="First">Oral Placebo<span class="Sup">*</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Number</p>
<p>Entered</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Healed/Evaluable</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Number</p>
<p>Entered</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Healed/Evaluable</p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Outpatients</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><p class="First">Week 2</p></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top">
<p class="First">69/182</p>
<p>(38%)<span class="Sup">â€ </span></p>
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top">
<p class="First">31/164</p>
<p>(19%)</p>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" valign="top">195</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top">188</td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Week 4</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top">
<p class="First">137/187</p>
<p>(73%)<span class="Sup">â€ </span></p>
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">76/168</p>
<p>(45%)</p>
</td>
</tr>
</tbody>
</table>
<p><span class="Sup">*</span>All patients were permitted antacids as needed for relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p><span class="Sup">â€ </span><span class="Italics">P</span>&lt;0.0001.</p>
<p>In these studies, patients treated with oral ZANTAC reported a reduction in both daytime and nocturnal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and they also consumed less antacid than the placebo-treated patients.</p>
<a name="id_4d605936-42f6-4c7c-b78f-02c4840d1ba8"></a><table width="0.000">
<caption><span>Table 4. Mean Daily Doses of Antacid</span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcer</span> Healed</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcer</span> Not Healed</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Oral ZANTAC</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.06</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.71</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">Oral placebo</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">0.71</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.43</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics">Pathological Hypersecretory Conditions (such as Zollinger-Ellison syndrome):</span></span> ZANTAC inhibits gastric acid secretion and reduces occurrence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in patients with pathological hypersecretion associated with Zollinger-Ellison syndrome, <span class="product-label-link" type="condition" conceptid="4246284" conceptname="Systemic mast cell disease">systemic mastocytosis</span>, and other pathological hypersecretory conditions (e.g., postoperative, "short-gut" syndrome, idiopathic). Use of oral ZANTAC was followed by healing of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in 8 of 19 (42%) patients who were intractable to previous therapy.</p>
<p>In a retrospective review of 52 Zollinger-Ellison patients given ZANTAC as a continuous IV infusion for up to 15 days, no patients developed complications of acid-peptic disease such as <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or perforation. Acid output was controlled to â‰¤10Â mEq/h.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_3c96a147-ed26-46ac-99dc-ebbd9da3fe0e"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ZANTAC Injection is indicated in some hospitalized patients with pathological hypersecretory conditions or intractable <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>, or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_5ff5dae2-1c1d-476f-bc90-69e60139065d"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">ZANTAC Injection is contraindicated for patients known to have <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_1bc54680-c799-4494-aa8a-3ce87c565e7c"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_dd72634d-f40f-4d36-9157-d6e3e70059ab"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<ol>
<li>Symptomatic response to therapy with ZANTAC does not preclude the presence of <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">gastric malignancy</span>.</li>
<li>Since ZANTAC is excreted primarily by the kidney, dosage should be adjusted in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (see <a href="#i4i_dosage_admin_id_6a5691bf-988a-4901-b28e-b556a940ccd7">DOSAGE AND ADMINISTRATION</a>). Caution should be observed in patients with hepatic dysfunction since ZANTAC is metabolized in the liver.</li>
<li>In controlled studies in normal volunteers, elevations in SGPT have been observed when H<span class="Sub">2</span>-antagonists have been administered intravenously at greater-than-recommended dosages for 5 days or longer. Therefore, it seems prudent in patients receiving IV ranitidine at dosages â‰¥100Â mg 4 times daily for periods of 5 days or longer to monitor SGPT daily (from day 5) for the remainder of IV therapy.</li>
<li><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> in association with rapid administration of ZANTAC Injection has been reported rarely, usually in patients with factors predisposing to cardiac rhythm disturbances. Recommended rates of administration should not be exceeded (see <a href="#i4i_dosage_admin_id_6a5691bf-988a-4901-b28e-b556a940ccd7">DOSAGE AND ADMINISTRATION</a>).</li>
<li>Rare reports suggest that ZANTAC may precipitate acute porphyric attacks in patients with acute <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>. ZANTAC should therefore be avoided in patients with a history of acute <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_50148c99-67a9-4c57-b3f9-25467a2faafa"></a><a name="section-6.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">False-positive tests for urine protein with MULTISTIX<span class="Sup">Â®</span> may occur during therapy with ZANTAC, and therefore testing with sulfosalicylic acid is recommended.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_102415b5-8931-4729-9807-c70a63eb8a44"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Ranitidine has been reported to affect the bioavailability of other drugs through several different mechanisms such as competition for renal tubular secretion, alteration of gastric pH, and inhibition of cytochrome P450 enzymes.</p>
<p><span class="Bold"><span class="Italics">Procainamide:</span></span> Ranitidine, a substrate of the renal organic cation transport system, may affect the clearance of other drugs eliminated by this route. High doses of ranitidine (e.g., such as those used in the treatment of Zollinger-Ellison syndrome) have been shown to reduce the renal excretion of procainamide and N-acetylprocainamide resulting in increased plasma levels of these drugs. Although this interaction is unlikely to be clinically relevant at usual ranitidine doses, it may be prudent to monitor for procainamide toxicity when administered with oral ranitidine at a dose exceeding 300 mg per day.</p>
<p><span class="Bold"><span class="Italics">Warfarin:</span></span> There have been reports of altered <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time among patients on concomitant warfarin and ranitidine therapy. Due to the narrow therapeutic index, close monitoring of increased or decreased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time is recommended during concurrent treatment with ranitidine.</p>
<p>Ranitidine may alter the absorption of drugs in which gastric pH is an important determinant of bioavailability. This can result in either an increase in absorption (e.g., triazolam, midazolam, glipizide) or a decrease in absorption (e.g., ketoconazole, atazanavir, delavirdine, gefitinib). Appropriate clinical monitoring is recommended.</p>
<p><span class="Bold"><span class="Italics">Atazanavir:</span></span> Atazanavir absorption may be impaired based on known interactions with other agents that increase gastric pH. Use with caution. See atazanavir label for specific recommendations.</p>
<p><span class="Bold"><span class="Italics">Delavirdine:</span></span> Delavirdine absorption may be impaired based on known interactions with other agents that increase gastric pH. Chronic use of H<span class="Sub">2</span>-receptor antagonists with delavirdine is not recommended.</p>
<p><span class="Bold"><span class="Italics">Gefitinib:</span></span> Gefitinib exposure was reduced by 44% with the coadministration of ranitidine and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> (dosed to maintain gastric pH above 5.0). Use with caution.</p>
<p><span class="Bold"><span class="Italics">Glipizide:</span></span> In diabetic patients, glipizide exposure was increased by 34% following a single 150-mg dose of oral ranitidine. Use appropriate clinical monitoring when initiating or discontinuing ranitidine.</p>
<p><span class="Bold"><span class="Italics">Ketoconazole:</span></span> Oral ketoconazole exposure was reduced by up to 95% when oral ranitidine was coadministered in a regimen to maintain a gastric pH of 6 or above. The degree of interaction with usual dose of ranitidine (150 mg twice daily) is unknown.</p>
<p><span class="Bold"><span class="Italics">Midazolam:</span></span> Oral midazolam exposure in 5 healthy volunteers was increased by up to 65% when administered with oral ranitidine at a dose of 150 mg twice daily. However, in another interaction study in 8 volunteers receiving IV midazolam, a 300 mg oral dose of ranitidine increased midazolam exposure by about 9%. Monitor patients for excessive or prolonged sedation when ranitidine is coadministered with oral midazolam.</p>
<p><span class="Bold"><span class="Italics">Triazolam:</span></span> Triazolam exposure in healthy volunteers was increased by approximately 30% when administered with oral ranitidine at a dose of 150 mg twice daily. Monitor patients for excessive or prolonged sedation.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_c16e7a23-f086-4bda-bff6-8d7c5def576a"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">There was no indication of tumorigenic or carcinogenic effects in life-span studies in mice and rats at oral dosages up to 2,000Â mg/kg/day.</p>
<p>Ranitidine was not mutagenic in standard bacterial tests (<span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span>, <span class="Italics">Escherichia coli</span>) for mutagenicity at concentrations up to the maximum recommended for these assays.</p>
<p>In a dominant lethal assay, a single oral dose of 1,000Â mg/kg to male rats was without effect on the outcome of 2 matings per week for the next 9Â weeks.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_521179e5-3c09-434f-973c-25a500f08b3a"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Bold"><span class="Italics">Teratogenic Effects:</span></span> Pregnancy Category B. Reproduction studies have been performed in rats and rabbits at oral doses up to 160Â times the human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to ZANTAC. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_e7ab8fad-e004-4a6a-888a-966afad6e88d"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Ranitidine is secreted in human milk. Caution should be exercised when ZANTAC is administered to a nursing mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_2812735c-f091-4062-bd7d-3c3a501e6b62"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and effectiveness of ZANTAC Injection have been established in the age-group of 1 month to 16Â years for the treatment of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>. Use of ZANTAC in this age-group is supported by adequate and well-controlled studies in adults, as well as additional pharmacokinetic data in pediatric patients, and an analysis of the published literature. </p>
<p>Safety and effectiveness in pediatric patients for the treatment of pathological hypersecretory conditions have not been established.</p>
<p>Limited data in neonatal patients (less than 1 month of age) receiving ECMO suggest that ZANTAC may be useful and safe for increasing gastric pH for patients at risk of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_9c2aa83f-9cdb-420f-83ac-799d012e6b1c"></a><a name="section-6.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of ZANTAC Injection did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects. However, in clinical studies of oral formulations of ZANTAC, of the total number of subjects enrolled in US and foreign controlled clinical trials, for which there were subgroup analyses, 4,197 were 65 and over, while 899 were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>This drug is known to be substantially excreted by the kidney and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, caution should be exercised in dose selection, and it may be useful to monitor renal function (see <a href="#i4i_section_id_0f92c969-1111-4c82-ae77-efbd479dfc97">CLINICAL PHARMACOLOGY: Pharmacokinetics: Geriatric Use</a> and <a href="#i4i_section_id_40a4d9c0-e743-4d4d-bee4-e3e361fa05c1">DOSAGE AND ADMINISTRATION: Dosage Adjustment for Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_8bcb37e5-a995-40d9-9558-0169aa949d06"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Transient <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at the site of IM injection has been reported. Transient local burning or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> has been reported with IV administration of ZANTAC.</p>
<p>The following have been reported as events in clinical trials or in the routine management of patients treated with oral or parenteral ZANTAC. The relationship to therapy with ZANTAC has been unclear in many cases. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, sometimes severe, seems to be related to administration of ZANTAC.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_834e6477-e2bd-48e4-acf1-d8cb5df0e334"></a><a name="section-7.1"></a><p></p>
<h2>Central Nervous System</h2>
<p class="First">Rarely, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>. Rare cases of reversible <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> have been reported, predominantly in severely ill elderly patients. Rare cases of reversible <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> suggestive of a change in accommodation have been reported. Rare reports of reversible involuntary motor disturbances have been received.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1c3e3a66-9001-4419-82dc-f2c32382ddce"></a><a name="section-7.2"></a><p></p>
<h2>Cardiovascular</h2>
<p class="First">As with other H<span class="Sub">2</span>-blockers, rare reports of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> such as <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, and premature ventricular beats.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_493c4852-a9d8-4597-98b6-908376e62aa6"></a><a name="section-7.3"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and rare reports of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2fdf767a-cf3f-4e45-8cac-5440806c3bf5"></a><a name="section-7.4"></a><p></p>
<h2>Hepatic</h2>
<p class="First">In normal volunteers, SGPT values were increased to at least twice the pretreatment levels in 6 of 12Â subjects receiving 100Â mg intravenously 4 times daily for 7Â days, and in 4 of 24Â subjects receiving 50Â mg intravenously 4 times daily for 5Â days. There have been occasional reports of hepatocellular, cholestatic, or mixed <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, with or without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. In such circumstances, ranitidine should be immediately discontinued. These events are usually reversible, but in rare circumstances <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has occurred. Rare cases of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> have also been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_05ae731e-4a5f-4c1c-936a-afeef82462af"></a><a name="section-7.5"></a><p></p>
<h2>Musculoskeletal</h2>
<p class="First">Rare reports of <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span> and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7db227c0-f1c0-4845-ab30-7d16b91331c5"></a><a name="section-7.6"></a><p></p>
<h2>Hematologic</h2>
<p class="First"> Blood count changes (<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>) have occurred in a few patients. These were usually reversible. Rare cases of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, sometimes with <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">marrow hypoplasia</span>, and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> and exceedingly rare cases of acquired immune <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0c427931-188e-419f-9848-9dff8c6df1d2"></a><a name="section-7.7"></a><p></p>
<h2>Endocrine</h2>
<p class="First">Controlled studies in animals and humans have shown no stimulation of any pituitary hormone by ZANTAC and no antiandrogenic activity, and cimetidine-induced <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> in hypersecretory patients have resolved when ZANTAC has been substituted. However, occasional cases of <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, and <span class="product-label-link" type="condition" conceptid="4087317" conceptname="Lack of libido">loss of libido</span> have been reported in male patients receiving ZANTAC, but the incidence did not differ from that in the general population. Rare cases of breast symptoms and conditions, including <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span> and <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, have been reported in both males and females.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dd64318a-ffe0-4e23-a720-c03f8fa47a01"></a><a name="section-7.8"></a><p></p>
<h2>Integumentary</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, including rare cases of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>. Rare cases of <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> and <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3a07831a-4707-4740-be54-72e6a6c59b7d"></a><a name="section-7.9"></a><p></p>
<h2>Respiratory</h2>
<p class="First">A large epidemiological study suggested an increased risk of developing <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> in current users of histamine-2-receptor antagonists (H<span class="Sub">2</span>RAs) compared to patients who had stopped H<span class="Sub">2</span>RA treatment, with an observed adjusted relative risk of 1.63 (95% CI, 1.07-2.48). However, a causal relationship between use of H<span class="Sub">2</span>RAs and <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9b734a71-89eb-4cc9-99cd-5638107a8cd6"></a><a name="section-7.10"></a><p></p>
<h2>Other</h2>
<p class="First">Rare cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>), <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">acute interstitial nephritis</span>, and small increases in serum creatinine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_add46dc3-c903-4644-b38c-bd0dcef94e72"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There has been virtually no experience with overdosage with ZANTAC Injection and limited experience with oral doses of ranitidine. Reported acute ingestions of up to 18Â g orally have been associated with transient adverse effects similar to those encountered in normal clinical experience (see <a href="#i4i_adverse_effects_id_8bcb37e5-a995-40d9-9558-0169aa949d06">ADVERSE REACTIONS</a>). In addition, abnormalities of gait and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> have been reported.</p>
<p>When overdosage occurs, clinical monitoring and supportive therapy should be employed.</p>
<p>Studies in dogs receiving dosages of ZANTAC in excess of 225Â mg/kg/day have shown muscular <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and rapid respiration. Single oral doses of 1,000Â mg/kg in mice and rats were not lethal. Intravenous LD<span class="Sub">50</span> values in mice and rats were 77 and 83Â mg/kg, respectively.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_6a5691bf-988a-4901-b28e-b556a940ccd7"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e3cd81c5-133b-4429-83c6-463e8fbcf739"></a><a name="section-9.1"></a><p></p>
<h2>Parenteral Administration</h2>
<p class="First">In some hospitalized patients with pathological hypersecretory conditions or intractable <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>, or in patients who are unable to take oral medication, ZANTAC Injection may be administered parenterally according to the following recommendations:</p>
<p><span class="Bold"><span class="Italics">Intramuscular Injection:</span></span> 50Â mg (2Â mL) every 6 to 8Â hours. (No dilution necessary.)</p>
<p><span class="Bold"><span class="Italics">Intermittent Intravenous Injection:</span></span></p>
<p><span class="Bold"><span class="Italics">a. Intermittent Bolus:</span></span> 50Â mg (2Â mL) every 6 to 8Â hours. Dilute ZANTAC Injection, 50Â mg, in 0.9% sodium chloride injection or other compatible IV solution (see <a href="#i4i_section_id_d8797748-6519-4f87-a14f-31a14dc717a9">Stability</a>) to a concentration no greater than 2.5Â mg/mL (20Â mL). Inject at a rate no greater than 4Â mL/min (5Â minutes).</p>
<p><span class="Bold"><span class="Italics">b. Intermittent Infusion:</span></span> 50Â mg (2Â mL) every 6 to 8Â hours. Dilute ZANTAC Injection, 50Â mg, in 5% dextrose injection or other compatible IV solution (see <a href="#i4i_section_id_d8797748-6519-4f87-a14f-31a14dc717a9">Stability</a>) to a concentration no greater than 0.5Â mg/mL (100Â mL). Infuse at a rate no greater than 5 to 7Â mL/min (15 to 20Â minutes).</p>
<p>In some patients it may be necessary to increase dosage. When this is necessary, the increases should be made by more frequent administration of the dose, but generally should not exceed 400Â mg/day.</p>
<p><span class="Italics"><span class="Bold">Continuous Intravenous Infusion:</span></span> Add ZANTAC Injection to 5% dextrose injection or other compatible IV solution (see <a href="#i4i_section_id_d8797748-6519-4f87-a14f-31a14dc717a9">Stability</a>). Deliver at a rate of 6.25Â mg/hour (e.g., 150Â mg [6Â mL] of ZANTAC Injection in 250Â mL of 5% dextrose injection at 10.7Â mL/hour).</p>
<p>For Zollinger-Ellison patients, dilute ZANTAC Injection in 5% dextrose injection or other compatible IV solution (see <a href="#i4i_section_id_d8797748-6519-4f87-a14f-31a14dc717a9">Stability</a>) to a concentration no greater than 2.5Â mg/mL. Start the infusion at a rate of 1.0Â mg/kg/hour. If after 4 hours either a measured gastric acid output is &gt;10Â mEq/hour or the patient becomes symptomatic, the dose should be adjusted upward in 0.5-mg/kg/hour increments, and the acid output should be remeasured. Dosages up to 2.5Â mg/kg/hour and infusion rates as high as 220Â mg/hour have been used.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_97ad1365-d352-424f-a429-0cbdeaa92577"></a><a name="section-9.2"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">While limited data exist on the administration of IV ranitidine to children, the recommended dose in pediatric patients is for a total daily dose of 2 to 4Â mg/kg, to be divided and administered every 6 to 8Â hours, up to a maximum of 50Â mg given every 6 to 8Â hours. This recommendation is derived from adult clinical studies and pharmacokinetic data in pediatric patients. Limited data in neonatal patients (less than 1 month of age) receiving ECMO have shown that a dose of 2Â mg/kg is usually sufficient to increase gastric pH to &gt;4 for at least 15Â hours. Therefore, doses of 2Â mg/kg given every 12 to 24Â hours or as a continuous infusion should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_40a4d9c0-e743-4d4d-bee4-e3e361fa05c1"></a><a name="section-9.3"></a><p></p>
<h2>Dosage Adjustment for Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">The administration of ranitidine as a continuous infusion has not been evaluated in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. On the basis of experience with a group of subjects with severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> treated with ZANTAC, the recommended dosage in patients with a creatinine clearance &lt;50Â mL/min is 50Â mg every 18 to 24Â hours. Should the patient's condition require, the frequency of dosing may be increased to every 12Â hours or even further with caution. Hemodialysis reduces the level of circulating ranitidine. Ideally, the dosing schedule should be adjusted so that the timing of a scheduled dose coincides with the end of hemodialysis.</p>
<p>Elderly patients are more likely to have decreased renal function, therefore caution should be exercised in dose selection, and it may be useful to monitor renal function (see <a href="#i4i_section_id_0f92c969-1111-4c82-ae77-efbd479dfc97">CLINICAL PHARMACOLOGY: Pharmacokinetics: Geriatric Use</a> and <a href="#i4i_geriatric_use_id_9c2aa83f-9cdb-420f-83ac-799d012e6b1c">PRECAUTIONS: Geriatric Use</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d8797748-6519-4f87-a14f-31a14dc717a9"></a><a name="section-9.4"></a><p></p>
<h2>Stability</h2>
<p class="First">Undiluted, ZANTAC Injection tends to exhibit a yellow color that may intensify over time without adversely affecting potency. ZANTAC Injection is stable for 48Â hours at room temperature when added to or diluted with most commonly used IV solutions, e.g., 0.9% sodium chloride injection, 5% dextrose injection, 10% dextrose injection, lactated ringer's injection, or 5% sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> injection.</p>
<p><span class="Bold">Note:</span> Parenteral drug products should be inspected visually for particulate matter and discoloration before administration whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_37514b1e-0099-4430-b186-7b2a1287483f"></a><a name="section-9.5"></a><p></p>
<h2>Directions for Dispensing</h2>
<p class="First"><span class="Bold"><span class="Italics">Pharmacy Bulk Packageâ€”Not for Direct Infusion:</span></span> The pharmacy bulk package is for use in a pharmacy admixture service only under a laminar flow hood. The closure should be penetrated only once with a sterile transfer set or other sterile dispensing device, which allows measured distribution of the contents, and the contents dispensed in aliquots using aseptic technique. CONTENTS SHOULD BE USED AS SOON AS POSSIBLE FOLLOWING INITIAL CLOSURE PUNCTURE. DISCARD ANY UNUSED PORTION WITHIN 24 HOURS OF FIRST ENTRY. Following closure puncture, container should be maintained below 30Â°C (86Â°F) under a laminar flow hood until contents are dispensed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_90b76b11-9b0c-4c27-8e52-729e48e5b89a"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">ZANTAC Injection, 25Â mg/mL, containing phenol 0.5% as preservative, in a 40-mL pharmacy bulk package (NDC 24987-364-01).</p>
<p><span class="Bold">Store between 4Â° and 25Â°C (39Â° and 77Â°F); excursions permitted to 30Â°C (86Â°F). Protect from light. Store vial in carton until time of use.</span></p>
<p>Covis</p>
<p>Distributed by Covis Pharmaceuticals, Inc.</p>
<p>Cary, NC 27511</p>
<p>Manufactured by GlaxoSmithKline</p>
<p>Barnard Castle, County Durham, DL12 8DT UK</p>
<p>ZANTAC is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc., used under license. </p>
<p>MULTISTIX is a registered trademark of Bayer Healthcare LLC.</p>
<p>Â©2012, Covis PHarmaceuticals, Inc. All rights reserved.</p>
<p>1000000</p>
<p>May 2012</p>
<p>100029</p>
<p>0103336</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_861d329f-4900-4430-bb50-39c42f605475"></a><a name="section-11"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel</span></p>
<p><span class="Bold">NDC 24987-364-01</span></p>
<p><span class="Bold">Zantac<span class="Sup">Â®</span></span></p>
<p><span class="Bold">(ranitidine hydrochloride) </span></p>
<p><span class="Bold">Injection</span></p>
<p><span class="Bold">25 mg/mL*</span></p>
<p><span class="Bold">40-mL Pharmacy Bulk Package â€“ Not for Direct Infusion</span></p>
<p><span class="Bold">Sterile <br>R<span class="Sub">x</span> only </span></p>
<p><span class="Bold">Contents should be used as soon as possible following initial closure puncture. Discard any unused portion within 24 hours of first entry.</span></p>
<p>*Each 1 mL of aqueous solution contains ranitidine 25 mg (as the hydrochloride); phenol 5 mg as preservative; monobasic potassium phosphate and dibasic sodium phosphate as buffers.</p>
<p>See package insert for Dosage and Administration and directions for use of Pharmacy Bulk Package.</p>
<p>Store between 4<span class="Sup">o</span> and 25<span class="Sup">o</span>C (39<span class="Sup">o</span> and 77<span class="Sup">o</span>F); excursions permitted to 30<span class="Sup">o</span>C (86<span class="Sup">o</span>F). Protect from light. Store vial in carton until time of use.</p>
<p>Zantac<span class="Sup">Â®</span> Injection tends to exhibit a yellow color that may intensify over time without adversely affecting potency.</p>
<p>Zantac is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc., used under license.</p>
<p>Distributed by: Covis Pharmaceuticals, Inc., Cary, NC 27511</p>
<p>Made in Singapore</p>
<p>100024</p>
<p>Rev. 6/12</p>
<p>10000000103303</p>
<div class="Figure">
<img alt="Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da7dbbe1-4f2d-4466-9573-8d239d112998&amp;name=f6e057d6-ec9a-45da-ba74-0ebda3fa873c-02.jpg"><p class="MultiMediaCaption">40 mL Pharmacy Bulk Package Label</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZANTACÂ 		
					</strong><br><span class="contentTableReg">ranitidine hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24987-364</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>RANITIDINE HYDROCHLORIDE</strong> (RANITIDINE) </td>
<td class="formItem">RANITIDINE</td>
<td class="formItem">25Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PHENOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM PHOSPHATE, MONOBASIC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (colorless to yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24987-364-01</td>
<td class="formItem">40 mL in 1 VIAL, PHARMACY BULK PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019090</td>
<td class="formItem">06/14/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Covis Pharmaceuticals, Inc.
							(969968986)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f6e057d6-ec9a-45da-ba74-0ebda3fa873c</div>
<div>Set id: da7dbbe1-4f2d-4466-9573-8d239d112998</div>
<div>Version: 3</div>
<div>Effective Time: 20130614</div>
</div>
</div>Â <div class="DistributorName">Covis Pharmaceuticals, Inc.</div></p>
</body></html>
